hat
Abitan Acetate te apwouve pa Administrasyon Manje Etazini ak Medikaman sou 28 avril 2011. FDA lapawòl te fè referans a yon esè klinik faz III kote itilizasyon abirateròn te asosye ak yon siviv medyàn 14.8 mwa kont 10.9 mwa ak plasebo; etid la te sispann bonè paske nan rezilta a siksè.
eng
Abiraterone acetate was approved by the United States Food and Drug Administration on April 28, 2011.The FDA press release made reference to a phase III clinical trial in which abiraterone use was associated with a median survival of 14.8 months versus 10.9 months with placebo; the study was stopped early because of the successful outcome.